

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/245130 A1

(43) International Publication Date
09 December 2021 (09.12.2021)

(51) International Patent Classification:

C07K 14/55 (2006.01) *A61P 35/00* (2006.01)
A61K 38/20 (2006.01) *C12N 15/85* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/064781

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

02 June 2021 (02.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20177974.1	03 June 2020 (03.06.2020)	EP
20202299.2	16 October 2020 (16.10.2020)	EP
63/116,102	19 November 2020 (19.11.2020)	US
20216052.9	21 December 2020 (21.12.2020)	EP
21160477.2	03 March 2021 (03.03.2021)	EP
21162030.7	11 March 2021 (11.03.2021)	EP

(71) Applicant: **ASCENDIS PHARMA ONCOLOGY DIVISION A/S** [DK/DK]; Tuborg Boulevard 12, 2900 Hellerup (DK).

(72) Inventors: **GUNNARSSON, Nina**; Ascendis Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup (DK). **MALECKIS, Matiss**; Ascendis Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup (DK). **ROSEN, David B**; Ascendis Pharma Inc., 500 Emerson Street, Palo Alto, California 94301 (US).

(74) Agent: **BÜCHEL, Edwin**; Patentanwälte Isenbruck Bösl Hörschler PartG mbB, Seckenheimer Landstraße 4, 68163 Mannheim (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: IL-2 SEQUENCES AND USES THEREOF

(57) Abstract: The present invention relates to an IL-2 protein sequence of the formula Ala - SEQ A - Cys * - SEQ B (I), wherein SEQ A has at least 94% sequence identity to SEQ ID NO:1; SEQ B has at least 94% sequence identity to SEQ ID NO:2; Ala is an alanine residue; and Cys* is a cysteine residue; to conjugates thereof and their uses in the treatment of cancer.

WO 2021/245130 A1